Levi & Korsinsky Urges LifeMD, Inc. (LFMD) Shareholders to Act Before Lead Plaintiff Deadline October 25, 2025

NEW YORK, NY / ACCESS Newswire / September 17, 2025 / If you suffered a loss on your LifeMD, Inc. (NASDAQ:LFMD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/lifemd-inc-lawsuit-submission-form?prid=167983&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call […]

Class Action Filed Against Lockheed Martin Corporation (LMT) Over Securities Violations – Contact Levi & Korsinsky Today

NEW YORK, NY / ACCESS Newswire / September 17, 2025 / If you suffered a loss on your Lockheed Martin Corporation (NYSE:LMT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/lockheed-martin-corporation-lawsuit-submission-form?prid=167982&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

/C O R R E C T I O N — JLL Income Property Trust/

In the news release, JLL Income Property Trust Acquires Raleigh Area Industrial Park, issued 17-Sep-2025 by JLL Income Property Trust over PR Newswire, we are advised by the company that the end of the first paragraph should read “approximately $190 million” rather than “approximately $196 million”, as originally issued inadvertently. The complete, corrected release follows:

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Snap Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SNAP

NEW YORK CITY, NY / ACCESS Newswire / September 17, 2025 / WHY: New York, N.Y., September 17, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Snap Inc. (NYSE:SNAP) between April 29, 2025 and August 5, 2025, both dates inclusive (the "Class Period"), both dates inclusive, of the

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Semler Scientific, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SMLR

NEW YORK, NY / ACCESS Newswire / September 17, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Semler Scientific, Inc. (NASDAQ:SMLR) between March 10, 2021 and April 15, 2025, both dates inclusive (the "Class Period"), of the important October 28, 2025 lead plaintiff deadline in the

Noble Panacea unlocks the night’s rhythm with the launch of The Peptide8 Night Serum at Château La Coste, an iconic arts venue in Provence, France with a curated guest list of talents from around the world including renowned actress, Naomie Harris

Noble Panacea is the only skincare brand founded by a Nobel Laureate in Chemistry-the late Professor Sir Fraser Stoddart. At the heart of every formula lies his groundbreaking discovery: OSMV™ (Organic Super Molecular Vessel™) Technology. This deep-tech encapsulation and delivery system has revolutionized skincare by protecting, programming, and precisely releasing potent active ingredients to dramatically

Netskope Announces Pricing of Initial Public Offering

Netskope, a leader in modern security and networking for the cloud and AI era, today announced the pricing of its initial public offering of 47,800,000 shares of its Class A common stock at a public offering price of $19.00 per share. All shares in the offering are being sold by Netskope. https://mma.prnewswire.com/media/1904293/Netskope_Logo.jpg The shares are

SABLE OFFSHORE DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Sable Offshore Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SOC

NEW YORK CITY, NY / ACCESS Newswire / September 17, 2025 / WHY: New York, N.Y., September 17, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sable Offshore Corp. (NYSE:SOC): (1) between May 19, 2025 and June 3, 2025, both dates inclusive (the "Class Period"); and/or (2) pursuant

Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025

Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne compared with placebo. Denifanstat (ASC40) demonstrated a favorable safety and tolerability profile. Treatment emergent adverse events (TEAEs) in the denifanstat (ASC40) group were comparable to placebo: 58.6% versus 56.3%. The majority of TEAEs were mild (Grade 1)

ROSEN, LEADING INVESTOR COUNSEL, Encourages Lantheus Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LNTH

NEW YORK, NY / ACCESS Newswire / September 17, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Lantheus Holdings, Inc. (NASDAQ:LNTH) between February 26, 2025 and August 5, 2025, both dates inclusive (the "Class Period"). A

Scroll to Top